Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania

Hillman Cancer Center at University of Pittsburgh Cancer Institute is a clinical research site located in Pittsburgh, Pennsylvania, United States 15232.

Crixeo Health Trust Score: 87/100 (GOOD). This profile has not yet been claimed by the site owner.

Hillman Cancer Center at University of Pittsburgh Cancer Institute has participated in 52 clinical trials.

Therapeutic areas: Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer.

Sponsors: University of Wisconsin, Madison, National Cancer Institute (NCI), Eastern Cooperative Oncology Group.

Sponsor Feasibility Report

Trust Score: 87/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Hillman Cancer Center at University of Pittsburgh Cancer Institute?

Hillman Cancer Center at University of Pittsburgh Cancer Institute has a Crixeo Trust Score of 87/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Hillman Cancer Center at University of Pittsburgh Cancer Institute conducted?

Hillman Cancer Center at University of Pittsburgh Cancer Institute has 52 clinical trials on record. Their work covers Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer.

Is Hillman Cancer Center at University of Pittsburgh Cancer Institute accredited by Crixeo Health?

Yes — Hillman Cancer Center at University of Pittsburgh Cancer Institute holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Hillman Cancer Center at University of Pittsburgh Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.